GH Research PLC

NASDAQ
GHRS
Stock
Yield per half year: +26.08%
Dividend yield: 0%
Sector: Healthcare

11.7 $

0 $ 0%
6.3 $
17.99 $

Min/max per year

Share chart GH Research PLC

Extended chart Simple chart
Financial Markets by TradingView

About GH Research PLC

GH Research PLC, a clinical-stage biopharmaceutical company, engages in developing various therapies to treat psychiatric and neurological disorders. The company develops 5-Methoxy-N,N-Dimethyltryptamine (5-MeO-DMT) therapies for the treatment of patients with treatment-resistant depression (TRD). Its lead program is GH001, an inhalable mebufotenin product candidate that has completed two Phase 1 clinical trials and Phase 1/2 clinical trial in patients with TRD.

more details
The company also develops GH002, an intravenous mebufotenin product candidate; and GH003, an intranasal mebufotenin product candidate, which are in preclinical development trials with a focus on psychiatric and neurological disorders. GH Research PLC was incorporated in 2018 and is based in Dublin, Ireland.
Add to compare list
Add to watchlist
Add to portfolio
Add to notification price

Main settings

IPO date 2021-06-25
ISIN IE000GID8VI0
Industry Biotechnology
Sector Health Care
Валюта usd
Валюта отчета usd
Сайт link
Change price per day: 0% (11.7)
Change price per week: -0.7634% (11.79)
Change price per month: +24.47% (9.4)
Change price per 3 month: +6.65% (10.97)
Change price per half year: +26.08% (9.28)
Change price per year: -9.51% (12.93)
Change price per 3 year: +30.14% (8.99)
Change price per year to date: +65.02% (7.09)
All parameters

Grade

Underestimation
Title Value Grade
P/S 0 0
P/BV 2.04 7
P/E 0 0
Efficiency
Title Value Grade
ROA, % -18.8 0
ROE, % -19.58 0
ROIC, % 0 0
Dividends
Title Value Grade
Dividend yield 0 0
DSI 0 0
Average dividend growth 0 0
Debt
Title Value Grade
Debt/EBITDA -0.0153 10
Debt/Ratio 0.0033 10
Debt/Equity 0.0521 10
Growth impulse
Title Value Grade
Yield Revenue, % 0 0
Yield Ebitda, % 13175.16 10
Yield EPS, % 4669.71 10
More

Main owners

Institutions Volume Share, %
BVF Inc. 10 400 158 19.99
RA Capital Management, L.P. 5 587 333 10.74
RTW Investments LP 3 327 129 6.39
FMR, LLC 3 136 869 6.03
Lynx1 Capital Management Lp 1 838 617 3.53
VR Adviser, LLC 1 318 327 2.53
Verition Fund Management, LLC 1 162 485 2.23
Cormorant Asset Management, LP 593 043 1.14
Deep Track Capital, LP 499 400 0.96
5AM Venture Management, LLC 404 404 0.78

Similar companies

P/E & P/BVEV/Ebitda & Debt/Ebitda


Company management

Head Job title Payment Year of birth
Mr. Florian Schonharting M.Sc. (Econ) Co-Founder & Non-Executive Chairman of the Board N/A 1969 (56 years)
Mr. Magnus Halle Co-Founder & MD of Ireland N/A 1997 (28 years)
Ms. Julie Ryan F.C.A. Vice President of Finance N/A 1986 (39 years)
Mr. Aaron Cameron M.B.A. Chief Operating Officer N/A 1985 (40 years)
Dr. Velichka Valcheva M.D. Chief Executive Officer N/A 1975 (50 years)

About company

Address: Ireland, Dublin D RY, Joshua Dawson House - Open in google maps, Open in yandex maps
Website: https://www.ghres.com